Skip to main content
Log in

Effect of propionyl-L-carnitine on experimental myocardial infarction in dogs

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Limitation on infarct size, using propionyl-L-carnitine (Sigma-Tau) by itself and with the calcium entry blocker, tiapamil (Hoffmann-LaRoche), was evaluated in two groups of ten dogs each, during chronic (9 days) myocardial infarction. There were eight dogs that served as the control group. A closed-chest model was used to produce the thrombus by placing a helically shaped copper wire in the LAD by catheter technique, under x-ray visualization. Necrotic tissue in serial transventricular sections were delineated by triphenyltetrazolium chloride and measured by computer technique, using an IBM PC interfaced with a digitizing pad, 9 days following occlusion. The mean total amount of necrosis in the propionyl-L-carnitine (7.4%) and the propionyl-L-carnitine/tiapamil (6.7%) groups were significantly less (p<.01) than found in the control (14.1%) group, reflecting a difference of 50 and 58%, respectively, between the treated groups and control. A number of significant between-group comparisons (p<.05 to p<.001), under the same conditions, were found for various ischemia, hemodynamic, and hematologic variables followed before and at 30, 60, 90, 120, and 180 minutes after occlusion, as well as on the second and ninth day. The results of this study strongly suggest that propionyl-L-carnitine and propionyl-L-carnitine with tiapamil has a protective effect on myocardial function, following thrombotic occlusion of the LAD, as well as limiting the resulting infarct size.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Opie LH. Metabolism of the heart. Am Heart J 1968;76:685.

    Article  PubMed  CAS  Google Scholar 

  2. Fritz IB, Kaplan E, Yue KTM. Specificity of carnitine action on fatty acid oxidation by heart muscle. Am J Physiol 1962;202:117.

    PubMed  CAS  Google Scholar 

  3. Shug AL, Thomsen JH, Folts JD, et al. Changes in tissue levels of carnitine and other metabolites during myocardial ischemia and anoxia. Arch Biochem Biophys 1978;187(1): 25–33.

    Article  PubMed  CAS  Google Scholar 

  4. Folts JD, Shug AL, Koke JR, et al. Protection of the ischemic dog myocardium with carnitine. Am J Cardiol 1978;41(7):1209–1214.

    Article  PubMed  CAS  Google Scholar 

  5. Shug AL, Shrago E, Bittar N, et al. Acyl-CoA inhibition of adenine nucleotide translocation in ischemic myocardium. Am J Physiol 1975;228(3):689–692.

    PubMed  CAS  Google Scholar 

  6. Giles DT. Calcium antagonists: An overview. Angiology 1982;33(8):489.

    Article  PubMed  CAS  Google Scholar 

  7. Winniford MD, Willerson TT, Hillis LD. Calcium antagonists in the treatment of individuals with ischemic heart disease. Angiology 1982;33(8):516.

    Article  Google Scholar 

  8. Kival J, Myerburg RJ. The hemodynamic effects of calcium channel blocking agents: A brief review. Angiology 1982; 33(8):516.

    Article  Google Scholar 

  9. Ruedy J. Verapamil (review article). Clin Invest Med 1981;4(2):129.

    PubMed  CAS  Google Scholar 

  10. Zsoter TT. Calcium antagonists. Am Heart J 1980;99(6):805.

    Article  PubMed  CAS  Google Scholar 

  11. Council on Scientific Affairs (AMA). Calcium channel agents. JAMA 1983;250(18):2522.

    Article  Google Scholar 

  12. Singh BN. Pharmacological basis for the therapeutic applications of slow-channel blocking drugs. Angiology 1982; 33(8):492.

    Article  PubMed  CAS  Google Scholar 

  13. Alps BJ, Wilson A. The beneficial effect of nicardipine compared with nifedipine and verapamil in limiting myocardial infarct size in baboons. Arzniem-Forsch/Drug Res 1983; 33(6):868.

    CAS  Google Scholar 

  14. Krikler DM, Harris L, Rowland E. Calcium-channel blockers and beta blockers: Advantages and disadvantages of combination therapy in chronic stable angina pectoris. Am Heart J 1982;104(3):702.

    Article  PubMed  CAS  Google Scholar 

  15. Chakravarti RN, Sharma PL, Anand IS, et al. Effects of verapamil (isoptin) on experimental myocardial infarction in rhesus monkeys. Indian J Med Res 1981;73:625.

    PubMed  CAS  Google Scholar 

  16. Kordenat RK. Electrocardiogram during experimental coronary thrombosis. J Electrocardiol 1976;9(1):41.

    Article  PubMed  CAS  Google Scholar 

  17. Kordenat RK, Leasure J. Effect of tiapamil on canine myocardial infarct size. Am Heart J 1986;111(3):502.

    Article  PubMed  CAS  Google Scholar 

  18. Kordenat RK, Kezdi P, Stanley EL. A new catheter technique for producing experimental coronary thrombosis and selective coronary visualization. Am Heart J 1972;83:360.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported by Sigma-Tau, Industrie Farmaceutiche Riunte S.p.A., Pomezia, Rome, Italy

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leasure, J.E., Kordenat, K. Effect of propionyl-L-carnitine on experimental myocardial infarction in dogs. Cardiovasc Drug Ther 5, 85–95 (1991). https://doi.org/10.1007/BF00128247

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00128247

Key Words

Navigation